EcoDrugPlus

Protein Kinase C, Zeta

Ensembl ID : ENSACIG00000005397
Gene Symbol: PRKCZ
1 Cross references
205 Possible Orthologues:

Protein Kinase D1

Ensembl ID : ENSACIG00000005253
Gene Symbol: PRKD1
1 Cross references
210 Possible Orthologues:

Protein Kinase D3

Ensembl ID : ENSACIG00000014766
Gene Symbol: PRKD3
2 Cross references
207 Possible Orthologues:

Protein Kinase D3

Ensembl ID : ENSACIG00000014609
Gene Symbol: PRKD3
1 Cross references
218 Possible Orthologues:

Protein Kinase, Dna-Activated, Catalytic Subunit

Ensembl ID : ENSACIG00000015308
Gene Symbol: PRKDC
1 Cross references
187 Possible Orthologues:

Protein Tyrosine Kinase 2

Ensembl ID : ENSACIG00000018814
Gene Symbol: PTK2
2 Cross references
241 Possible Orthologues:

Protein Tyrosine Kinase 2 Beta, B

Ensembl ID : ENSACIG00000003644
Gene Symbol: PTK2BB
1 Cross references
196 Possible Orthologues:

Protein Tyrosine Phosphatase Non-Receptor Type 11a

Ensembl ID : ENSACIG00000007294
Gene Symbol: PTPN11A
1 Cross references
253 Possible Orthologues:

Protein Tyrosine Phosphatase Receptor Type B

Ensembl ID : ENSACIG00000007367
Gene Symbol: PTPRB
2 Cross references
193 Possible Orthologues:

Purinergic Receptor P2x, Ligand-Gated Ion Channel, 3a

Ensembl ID : ENSACIG00000006557
Gene Symbol: P2RX3A
1 Cross references
194 Possible Orthologues:

Purinergic Receptor P2x, Ligand-Gated Ion Channel, 3b

Ensembl ID : ENSACIG00000015356
Gene Symbol: P2RX3B
1 Cross references
200 Possible Orthologues:

Purinergic Receptor P2x, Ligand-Gated Ion Channel, 7

Ensembl ID : ENSACIG00000009633
Gene Symbol: P2RX7
1 Cross references
195 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).